HAVCR2 and cancer: The HAVCR2/TIM-3 molecule has been described as a checkpoint inhibitor and key regulator of the immune response acting by inhibiting T cell responses in both autoimmunity and cancer initiation and progression, as well as suppressing macrophage activation following PD-1 inhibition.